~~<i id='236AE78667'><strike id='236AE78667'><tt id='236AE78667'><pre id='236AE78667'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：fashion 2025-09-05 11:17:12 - browse：9

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Sanders adds drug shortage policies to pandemic preparedness bill

leisure time

hotspot

Wikipedia

explore

hotspot

focus

UniversityofPennsylvaniahospitalcomplexJonLovette/AlamyMercyPhiladelphiaHospitalwasplanningonshuttin

WSS

A public scorecard can help hold safety

How Medicaid coverage policies for immigrants impact new moms

Community Health Systems hospitals under DOJ investigation

STAT Virtual Event: The State of Biosimilars: What to Watch

Sanofi seeks simpler, safer CRISPR sickle cell cure

Why palliative psychiatry is worth discussing

hotspot

leisure time

leisure time

Medicare proposal to cover medical devices draws a mixed reaction

Alabama frozen embryo ruling has major implications for IVF clinics

Cancer drug shortages should be causing more outrage

With competition flaring, obesity drug hits goal in liver disease study

Continuity nursing helped my family in our darkest PICU moments

Antivenom research: Lessons from HIV applied in search for universal antidote

As demand for Covid shots wanes, Moderna seeks its next success

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

23andMe had bad news about my health. I wish a person had delivered it

He's a Nobel laureate. Critics say he was misleading on Covid

hotspot

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Sanders adds drug shortage policies to pandemic preparedness bill

How Medicaid coverage policies for immigrants impact new moms

Startup Neumora takes a novel depression drug to Phase 3

AI can’t replace a physician’s gut feeling

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Wikipedia

explore

hotspot

focus